首页 > 最新文献

Profiles of drug substances, excipients, and related methodology最新文献

英文 中文
Remdesivir
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-02-01 DOI: 10.1007/s40278-023-34554-z
Ahmed H H Bakheit, H. Darwish, I. Darwish, Ahmed I. Al-Ghusn
{"title":"Remdesivir","authors":"Ahmed H H Bakheit, H. Darwish, I. Darwish, Ahmed I. Al-Ghusn","doi":"10.1007/s40278-023-34554-z","DOIUrl":"https://doi.org/10.1007/s40278-023-34554-z","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"9 1","pages":"71 - 108"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79027077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface. 前言。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.1016/S1871-5125(23)00009-2
Abdulrahman A Al-Majed
{"title":"Preface.","authors":"Abdulrahman A Al-Majed","doi":"10.1016/S1871-5125(23)00009-2","DOIUrl":"https://doi.org/10.1016/S1871-5125(23)00009-2","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"48 ","pages":"ix"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9361385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crizotinib: A comprehensive profile. 克唑替尼:全面概况。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.1016/bs.podrm.2022.11.002
Ahmed A Abdelgalil, Hamad M Alkahtani

Crizotinib, approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK) It used for treatment of the patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. This chapter provides a complete review of crizotinib including nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of crizotinib. In addition, the chapter also includes review of several methods for separation of crizotinib using chromatographic techniques.

克唑替尼于2011年获批,是首个获批靶向间变性淋巴瘤激酶(ALK)的抑制剂,用于治疗间变性淋巴瘤激酶(ALK)阳性的转移性非小细胞肺癌(NSCLC)患者。本章对克唑替尼的命名、理化性质、制备方法、鉴定技术、各种定性和定量分析技术以及克唑替尼的药理学等方面进行了全面的综述。此外,本章还回顾了几种使用色谱技术分离克唑替尼的方法。
{"title":"Crizotinib: A comprehensive profile.","authors":"Ahmed A Abdelgalil,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2022.11.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2022.11.002","url":null,"abstract":"<p><p>Crizotinib, approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK) It used for treatment of the patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. This chapter provides a complete review of crizotinib including nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of crizotinib. In addition, the chapter also includes review of several methods for separation of crizotinib using chromatographic techniques.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"48 ","pages":"39-69"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9315710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lapatinib: A comprehensive profile. 拉帕替尼:全面的概况。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.1016/bs.podrm.2022.11.005
Ahmed A Abdelgalil, Hamad M Alkahtani

Lapatinib is an anticancer used for treatment of the patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine or with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer. This comprehensive profile of Lapatinib gives more detailed information about the description, formulae, Elemental Analysis, Uses and application. Furthermore, methods and schemes are outlined for the preparation of the drug substance. The physical properties of the medication include constant of ionization, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal conduct and spectroscopic studies are investigated. The methods employed in bulk medicines and/or in pharmaceutical formulations to analyze the drug substance include spectrophotometric, electrochemical and the chromatographic methods are indicated. Other studies on this drug substance include drug stability, pharmaceutical applications, mechanism of action, pharmacodynamics, and a dosing information are also reviewed.

拉帕替尼是一种抗癌药物,用于治疗晚期转移性乳腺癌患者,与化疗药物卡培他滨或来曲唑联合用于治疗绝经后激素受体阳性转移性乳腺癌妇女。拉帕替尼的综合简介提供了更详细的信息,包括描述、配方、元素分析、用途和应用。此外,还概述了该原料药的制备方法和方案。研究了药物的物理性质,包括电离常数、溶解度、x射线粉末衍射图、差示扫描量热、热传导和光谱研究。原料药和/或制剂中用于分析原料药的方法包括分光光度法、电化学法和色谱法。对该原料药的其他研究包括药物稳定性、药物应用、作用机制、药效学和给药信息进行了综述。
{"title":"Lapatinib: A comprehensive profile.","authors":"Ahmed A Abdelgalil,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2022.11.005","DOIUrl":"https://doi.org/10.1016/bs.podrm.2022.11.005","url":null,"abstract":"<p><p>Lapatinib is an anticancer used for treatment of the patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine or with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer. This comprehensive profile of Lapatinib gives more detailed information about the description, formulae, Elemental Analysis, Uses and application. Furthermore, methods and schemes are outlined for the preparation of the drug substance. The physical properties of the medication include constant of ionization, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal conduct and spectroscopic studies are investigated. The methods employed in bulk medicines and/or in pharmaceutical formulations to analyze the drug substance include spectrophotometric, electrochemical and the chromatographic methods are indicated. Other studies on this drug substance include drug stability, pharmaceutical applications, mechanism of action, pharmacodynamics, and a dosing information are also reviewed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"48 ","pages":"135-166"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9315709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remdesivir. 瑞德西韦
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 Epub Date: 2023-02-09 DOI: 10.1016/bs.podrm.2022.11.003
Ahmed H Bakheit, Hany Darwish, Ibrahim A Darwish, Ahmed I Al-Ghusn

Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations.

雷米地韦以 Veklury 品牌销售,是一种具有广泛活性的抗病毒药物。在 COVID-19 大流行期间,有多个国家批准使用 Remdesivir 治疗 COVID-19。Remdesivir 最初被设计用于治疗丙型肝炎,但后来对埃博拉病毒病和玛堡病毒感染进行了测试。雷米替韦是一种原药,旨在促进 GS-441524 单磷酸在细胞内的转运,并随后将其生物转化为 GS-441524 三磷酸,这是一种病毒 RNA 聚合酶的核糖核苷酸类似物抑制剂。本章旨在全面综述雷米替韦(GS-5734),包括其命名、理化性质、制备方法、鉴定程序、多种定性和定量分析技术、ADME 特征和药理作用。此外,本章还提供了多种色谱和光谱技术,用于在复方制剂中分离溴莫尼定和其他药物。
{"title":"Remdesivir.","authors":"Ahmed H Bakheit, Hany Darwish, Ibrahim A Darwish, Ahmed I Al-Ghusn","doi":"10.1016/bs.podrm.2022.11.003","DOIUrl":"10.1016/bs.podrm.2022.11.003","url":null,"abstract":"<p><p>Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"48 ","pages":"71-108"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9331082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmaceutical based cosmetic serums. 基于药物的化妆品血清。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.1016/bs.podrm.2022.11.006
Nimra Khan, Sofia Ahmed, Muhammad Ali Sheraz, Zubair Anwar, Iqbal Ahmad

The growth and demand for cosmeceuticals (cosmetic products that have medicinal or drug-like benefits) have been enhanced for the last few decades. Lately, the newly invented dosage form, i.e., the pharmaceutical-based cosmetic serum has been developed and widely employed in various non-invasive cosmetic procedures. Many pharmaceutical-based cosmetic serums contain natural active components that claim to have a medical or drug-like effect on the skin, hair, and nails, including anti-aging, anti-wrinkle, anti-acne, hydrating, moisturizing, repairing, brightening and lightening skin, anti-hair fall, anti-fungal, and nail growth effect, etc. In comparison with other pharmaceutical-related cosmetic products (creams, gels, foams, and lotions, etc.), pharmaceutical-based cosmetic serums produce more rapid and incredible effects on the skin. This chapter provides detailed knowledge about the different marketed pharmaceutical-based cosmetic serums and their several types such as facial serums, hair serums, nail serums, under the eye serum, lip serum, hand, and foot serum, respectively. Moreover, some valuable procedures have also been discussed which provide prolong effects with desired results in the minimum duration of time after the few sessions of the serum treatment.

在过去的几十年里,药妆品(具有药用或类似药物功效的化妆品)的增长和需求得到了加强。近年来,新发明的剂型,即以药物为基础的美容血清已被开发并广泛应用于各种非侵入性美容手术。许多以药物为基础的化妆品精华液含有天然活性成分,声称对皮肤、头发和指甲有医疗或药物般的作用,包括抗衰老、抗皱、抗痤疮、补水、保湿、修护、提亮肤色、防脱发、抗真菌和指甲生长等作用。与其他与药物相关的化妆品(面霜、凝胶、泡沫和乳液等)相比,基于药物的化妆品血清对皮肤产生更迅速和令人难以置信的效果。本章详细介绍了不同的已上市的基于药物的化妆品血清及其几种类型,如面部血清、头发血清、指甲血清、眼下血清、唇部血清、手部血清和足部血清。此外,还讨论了一些有价值的程序,这些程序在几次血清治疗后的最短时间内提供延长效果和期望的结果。
{"title":"Pharmaceutical based cosmetic serums.","authors":"Nimra Khan,&nbsp;Sofia Ahmed,&nbsp;Muhammad Ali Sheraz,&nbsp;Zubair Anwar,&nbsp;Iqbal Ahmad","doi":"10.1016/bs.podrm.2022.11.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2022.11.006","url":null,"abstract":"<p><p>The growth and demand for cosmeceuticals (cosmetic products that have medicinal or drug-like benefits) have been enhanced for the last few decades. Lately, the newly invented dosage form, i.e., the pharmaceutical-based cosmetic serum has been developed and widely employed in various non-invasive cosmetic procedures. Many pharmaceutical-based cosmetic serums contain natural active components that claim to have a medical or drug-like effect on the skin, hair, and nails, including anti-aging, anti-wrinkle, anti-acne, hydrating, moisturizing, repairing, brightening and lightening skin, anti-hair fall, anti-fungal, and nail growth effect, etc. In comparison with other pharmaceutical-related cosmetic products (creams, gels, foams, and lotions, etc.), pharmaceutical-based cosmetic serums produce more rapid and incredible effects on the skin. This chapter provides detailed knowledge about the different marketed pharmaceutical-based cosmetic serums and their several types such as facial serums, hair serums, nail serums, under the eye serum, lip serum, hand, and foot serum, respectively. Moreover, some valuable procedures have also been discussed which provide prolong effects with desired results in the minimum duration of time after the few sessions of the serum treatment.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"48 ","pages":"167-210"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9315708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Brimonidine. Brimonidine。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.1016/bs.podrm.2022.11.001
Ahmed H Bakheit, Ahmed M Alomar, Hany Darwish, Hamad M Alkahtani

Brimonidine is a highly selective 2-adrenoceptor agonist that lowers intraocular pressure (IOP) by decreasing aqueous humor production and increasing aqueous humor outflow via the uveoscleral route. Brimonidine is used to treat glaucoma and other eye conditions. Brimonidine is a topical medication that is used mainly to treat open-angle glaucoma and ocular hypertension in the eyelids. The purpose of this chapter is to provide a comprehensive discussion of Brimonidine's nomenclature, physiochemical properties, preparation methods, identification procedures, and numerous qualitative and quantitative analytical techniques, as well as its ADME profiles and pharmacological effects. In addition, the chapter contains numerous approaches for separating brimonidine from other medications in combination formulations utilizing chromatographic techniques and other spectroscopic approaches.

溴莫尼定是一种高选择性2-肾上腺素能受体激动剂,通过减少房水产生和增加房水经巩膜途径流出来降低眼压。溴硝定用于治疗青光眼和其他眼部疾病。溴莫尼定是一种局部用药,主要用于治疗开角型青光眼和眼睑高眼压。本章的目的是提供一个全面的讨论溴胺定的命名法,理化性质,制备方法,鉴定程序,以及众多定性和定量分析技术,以及它的ADME谱和药理作用。此外,本章包含了许多方法分离溴胺从其他药物组合制剂利用色谱技术和其他光谱方法。
{"title":"Brimonidine.","authors":"Ahmed H Bakheit,&nbsp;Ahmed M Alomar,&nbsp;Hany Darwish,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2022.11.001","DOIUrl":"https://doi.org/10.1016/bs.podrm.2022.11.001","url":null,"abstract":"<p><p>Brimonidine is a highly selective 2-adrenoceptor agonist that lowers intraocular pressure (IOP) by decreasing aqueous humor production and increasing aqueous humor outflow via the uveoscleral route. Brimonidine is used to treat glaucoma and other eye conditions. Brimonidine is a topical medication that is used mainly to treat open-angle glaucoma and ocular hypertension in the eyelids. The purpose of this chapter is to provide a comprehensive discussion of Brimonidine's nomenclature, physiochemical properties, preparation methods, identification procedures, and numerous qualitative and quantitative analytical techniques, as well as its ADME profiles and pharmacological effects. In addition, the chapter contains numerous approaches for separating brimonidine from other medications in combination formulations utilizing chromatographic techniques and other spectroscopic approaches.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"48 ","pages":"1-37"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9320806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Vandetanib. 咒骂。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.1016/bs.podrm.2022.11.004
Ahmed I Al-Ghusn, Ahmed H Bakheit, Mohamed W Attwa, Haitham AlRabiah

Vandetanib is an anti-cancer drug called an antineoplastic kinase inhibitor. The FDA authorized vandetanib on April6, 2011 for the treatment of nonresectable, locally progressed, or metastatic medullary thyroid carcinoma in adults. Because Vandetanib can make the Q-T interval last longer, it shouldn't be given to people with serious heart problems like congenital long QT syndrome or heart failure that hasn't been fixed yet. This chapter provides an overview of Vandetanib's physical and molecular properties, mode of action, pharmacokinetics, and common applications. In furthermore, a detailed summary of the reported techniques of Vandetanib measurement will be provided to assist analysts in selecting the most practical approach for its estimation in routine analysis. This chapter will also explain the synthesis methods developed in the preparation of vandetanib as well as pharmacology of its. In addition, this section summarizes the analytical and characterization techniques utilized to characterize vandetanib row material.

万德替尼是一种抗癌药物,被称为抗肿瘤激酶抑制剂。FDA于2011年4月6日批准vandetanib用于成人不可切除、局部进展或转移性甲状腺髓样癌的治疗。因为Vandetanib可以延长Q-T间期,它不应该给那些有严重心脏问题的人,比如先天性长QT综合征或心脏衰竭,这些问题还没有得到解决。本章概述了Vandetanib的物理和分子特性、作用方式、药代动力学和常见应用。此外,将提供Vandetanib测量报告技术的详细总结,以帮助分析人员在常规分析中选择最实用的方法进行估计。本章还将介绍万德替尼的合成方法及其药理作用。此外,本节总结了用于表征vandetanib材料的分析和表征技术。
{"title":"Vandetanib.","authors":"Ahmed I Al-Ghusn,&nbsp;Ahmed H Bakheit,&nbsp;Mohamed W Attwa,&nbsp;Haitham AlRabiah","doi":"10.1016/bs.podrm.2022.11.004","DOIUrl":"https://doi.org/10.1016/bs.podrm.2022.11.004","url":null,"abstract":"<p><p>Vandetanib is an anti-cancer drug called an antineoplastic kinase inhibitor. The FDA authorized vandetanib on April6, 2011 for the treatment of nonresectable, locally progressed, or metastatic medullary thyroid carcinoma in adults. Because Vandetanib can make the Q-T interval last longer, it shouldn't be given to people with serious heart problems like congenital long QT syndrome or heart failure that hasn't been fixed yet. This chapter provides an overview of Vandetanib's physical and molecular properties, mode of action, pharmacokinetics, and common applications. In furthermore, a detailed summary of the reported techniques of Vandetanib measurement will be provided to assist analysts in selecting the most practical approach for its estimation in routine analysis. This chapter will also explain the synthesis methods developed in the preparation of vandetanib as well as pharmacology of its. In addition, this section summarizes the analytical and characterization techniques utilized to characterize vandetanib row material.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"48 ","pages":"109-134"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9320807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Application of chemometrics using direct spectroscopic methods as a QC tool in pharmaceutical industry and their validation. 化学计量学直接光谱法在制药工业中的应用及其验证。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-01-01 DOI: 10.1016/bs.podrm.2021.10.006
L. Wulandari, R. Idroes, T. R. Noviandy, G. Indrayanto
{"title":"Application of chemometrics using direct spectroscopic methods as a QC tool in pharmaceutical industry and their validation.","authors":"L. Wulandari, R. Idroes, T. R. Noviandy, G. Indrayanto","doi":"10.1016/bs.podrm.2021.10.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2021.10.006","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"60 1","pages":"327-379"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79860297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Loratadine.
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-01-01 DOI: 10.1016/bs.podrm.2021.10.002
N. AlMasoud, Ahmed H H Bakheit, M. F. Alshammari, H. Abdel‐Aziz, H. Alrabiah
{"title":"Loratadine.","authors":"N. AlMasoud, Ahmed H H Bakheit, M. F. Alshammari, H. Abdel‐Aziz, H. Alrabiah","doi":"10.1016/bs.podrm.2021.10.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2021.10.002","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"82 1","pages":"55-90"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82162457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Profiles of drug substances, excipients, and related methodology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1